KLRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Consistent with these data, blocking NKG2D in T cells impaired NKG2D-mediated cytotoxicity by decreasing GzmB production (Fig. 4b, c), and ultimately inhibited CML-RAE-1γ-Dex-induced T-cell responses.